MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/15/2006 10:38:19 AM
	Read Replies (1) of 1826

MethylGene to Increase Investment in HDAC and Kinase 'c-MET' Small Molecule Programs Prioritizes Oncology Programs MONTREAL, QUEBEC -- (MARKET WIRE) -- December 15, 2006 -- MethylGene Inc. (TSX: MYG) today announced that based on recent R&D successes in its small molecule oncology programs and a strategic review of its cancer pipeline, it will not pursue additional clinical trials for MG98, its second generation antisense compound targeting DNA methyltransferase. This decision is made with its North American co-development partner for the compound, MGI PHARMA, INC. The companies have agreed to seek alternative development partners or arrangements for the MG98 program.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next